On January 12, AbbVie announced that it had reached an agreement with the Trump administration on participation in its most favored nation (MFN) pricing initiative, and making certain medications available through its direct-to-consumer platform. With the various agreements made with 15 other pharmaceutical companies, specific drugs were not disclosed. This is the first time in … Continue reading AbbVie, MFN, and a World of Ambiguity